Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
72.02 USD | -0.39% | -2.69% | +0.56% |
Financials (USD)
Sales 2024 * | 662M | Sales 2025 * | 923M | Capitalization | 7.62B |
---|---|---|---|---|---|
Net income 2024 * | -59M | Net income 2025 * | 108M | EV / Sales 2024 * | 10.4 x |
Net cash position 2024 * | 755M | Net cash position 2025 * | 839M | EV / Sales 2025 * | 7.35 x |
P/E ratio 2024 * |
-115
x | P/E ratio 2025 * |
63.8
x | Employees | 610 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.55% |
Latest transcript on Intra-Cellular Therapies, Inc.
1 day | -1.31% | ||
1 week | -3.01% | ||
Current month | +4.48% | ||
1 month | +4.48% | ||
3 months | +3.49% | ||
6 months | +48.92% | ||
Current year | +0.95% |
Managers | Title | Age | Since |
---|---|---|---|
Sharon Mates
CEO | Chief Executive Officer | 71 | 13-08-28 |
Director of Finance/CFO | 67 | 13-08-28 | |
Michael Halstead
PSD | President | 51 | 14-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Rory Riggs
BRD | Director/Board Member | 71 | 14-01-07 |
Joel Marcus
BRD | Director/Board Member | 76 | 13-08-28 |
Director/Board Member | 67 | 14-01-07 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.14% | 16 M€ | -5.68% | ||
0.45% | 0 M€ | 0.00% | - | |
0.40% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-30 | 72.02 | -0.39% | 493 400 |
24-04-29 | 72.3 | -1.31% | 552,276 |
24-04-26 | 73.26 | +1.57% | 594,803 |
24-04-25 | 72.13 | -1.35% | 658,777 |
24-04-24 | 73.12 | -1.20% | 736,512 |
Delayed Quote Nasdaq, April 29, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.95% | 7.62B | |
-3.45% | 87.17B | |
+1.97% | 40.1B | |
+57.67% | 25.12B | |
-14.82% | 15.59B | |
-8.82% | 12B | |
-16.29% | 11.8B | |
-41.58% | 11.8B | |
+7.49% | 8.81B | |
-10.53% | 8.24B |
- Stock Market
- Equities
- ITCI Stock